BridgeBio Pharma Enters Genetic Disease Alliance

BridgeBio Pharma LLC and Cincinnati Children's Hospital Medical Center have entered into a research collaboration to identify and develop genetic disease therapies. This partnership will combine BridgeBio's therapeutic development expertise with Cincinnati Children's world-class researchers and clinicians.

BridgeBio will have the opportunity to sponsor and collaboratively develop selected research programs. The agreement represents a flexible model that facilitates accelerated genetic disease research.

"BridgeBio is privileged to partner with leading experts at Cincinnati Children's, an institution whose impact on science and patients we admire. We hope we can help advance the mission by partnering to move therapies forward to patients," said Neil Kumar, co-founder and chief executive officer of BridgeBio. 

"We are excited to launch this new alliance with BridgeBio to bring new and innovative therapies to some of the most vulnerable patients impacted by rare and complex genetic diseases," said Margaret Hostetter, MD, chief medical officer of Cincinnati Children's and Director, Cincinnati Children's Research Foundation.